keyword
MENU ▼
Read by QxMD icon Read
search

metformin users

keyword
https://www.readbyqxmd.com/read/29329345/survival-benefit-associated-with-metformin-use-in-inoperable-non-small-cell-lung-cancer-patients-with-diabetes-a-population-based-retrospective-cohort-study
#1
Min-Chun Chuang, Yao-Hsu Yang, Ying-Huang Tsai, Meng-Jer Hsieh, Yu-Ching Lin, Chin-Kuo Lin, Pau-Chung Chen, Tsung-Ming Yang
OBJECTIVE: To evaluate the effects of metformin use on the survival of inoperable non-small cell lung cancer (NSCLC) patients with diabetes using the Taiwanese National Health Insurance Research Database. RESEARCH DESIGN AND METHODS: In total, 7,620 patients were eligible in this study, among them, 3,578 patients were metformin users and 4,042 were non-users. Propensity score matching was used to reduce possible confounding factors. In total, 4,182 patients (2,091 matched pairs) were included in the matched cohort...
2018: PloS One
https://www.readbyqxmd.com/read/29325084/metformin-use-reverses-the-increased-mortality-associated-with-diabetes-mellitus-during-tuberculosis-treatment
#2
Nicholas R Degner, Jann-Yuan Wang, Jonathan E Golub, Petros C Karakousis
Background: The global type 2 diabetes mellitus (DM) epidemic threatens progress made in reducing tuberculosis (TB)-related mortality worldwide. Previous clinical studies have not fully evaluated potential confounding variables in addressing the impact of DM on TB treatment outcomes. The antidiabetic agent metformin regulates autophagy and may play a role as a host-directed therapeutic adjuvant to antitubercular treatment. Methods: We conducted a retrospective cohort study comprising patients aged ≥13 years undergoing treatment for culture-confirmed, drug-susceptible pulmonary TB...
January 6, 2018: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/29278713/is-metformin-beneficial-for-heart-failure-in-patients-with-type-2-diabetes
#3
Milton Packer
Heart failure is a common and serious cardiovascular complication of type 2 diabetes. Many antihyperglycemic drugs can increase the risk of heart failure. However, it is commonly believed that metformin - the first-line treatment for type 2 diabetes - reduces the risk of and improves the clinical course of heart failure. It is estimated that 20-25% of patients taking metformin have heart failure. Metformin has been shown to have favorable effects on the course of heart failure in experimental models. Furthermore, when compared with other antihyperglycemic medications in nonrandomized epidemiological studies, metformin users had a lower risk of new-onset heart failure and a lower risk of death if they already had heart failure...
December 23, 2017: Diabetes Research and Clinical Practice
https://www.readbyqxmd.com/read/29258504/dipeptidyl-peptidase-4-inhibitor-decreases-the-risk-of-atrial-fibrillation-in-patients-with-type-2-diabetes-a-nationwide-cohort-study-in-taiwan
#4
Chia-Yu Chang, Yung-Hsin Yeh, Yi-Hsin Chan, Jia-Rou Liu, Shang-Hung Chang, Hsin-Fu Lee, Lung-Sheng Wu, Kun-Chi Yen, Chi-Tai Kuo, Lai-Chu See
BACKGROUND: Whether dipeptidyl peptidase-4 inhibitor (DPP4i) is associated with a lower risk of new-onset atrial fibrillation (AF) in patients with diabetes remains unclear. This study aimed to evaluate the risk of AF associated with use of DPP4i among a longitudinal cohort of patients with diabetes. METHODS: Over a 3-year period, 480,000 patients with diabetes were analyzed utilizing Taiwan's National Health Insurance Research Database and 90,880 patients taking metformin as first-line therapy were enrolled...
December 19, 2017: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/29246826/metformin-and-skin-cancer-risk-in-taiwanese-patients-with-type-2-diabetes
#5
Chin-Hsiao Tseng
BACKGROUND: Metformin, an antidiabetic drug, is associated with decreased cancer risk, but its effect on skin cancer is unknown. OBJECTIVE: To evaluate skin cancer risk associated with metformin use. METHODS: Matched pairs of 16237 ever and never metformin users were retrospectively enrolled from patients with new-onset type 2 diabetes diagnosed between 1999 and 2005 from Taiwan's National Health Insurance database, and followed until December 31, 2011...
December 13, 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/29245991/the-impact-of-metformin-use-on-survival-in-prostate-cancer-a-systematic-review-and-meta-analysis
#6
Yao Xiao, Lei Zheng, Zubing Mei, Changbao Xu, Changwei Liu, Xiaohan Chu, Bin Hao
Background: Metformin has been implicated to reduce the risk of prostate cancer (PCa) beyond its glucose-lowering effect. However, the influence of metformin on prognosis of PCa is often controversial. Results: A total of 13 cohort studies encompassing 177,490 individuals were included in the meta-analysis. Data on overall survival (OS) and cancer-specific survival (CSS) was extracted from 8 and six studies, respectively. Comparing metformin users with non-metformin users, the pooled hazard ratios (HRs) for OS and CSS were 0...
November 21, 2017: Oncotarget
https://www.readbyqxmd.com/read/29215149/pregnancy-outcomes-in-women-on-metformin-for-diabetes-or-other-indications-among-those-seeking-teratology-information-services
#7
Alice Panchaud, Valentin Rousson, Thierry Vial, Nathalie Bernard, David Baud, Emmanuelle Amar, Marco De Santis, Alessandra Pistelli, Anne Dautriche, Frederique Beau-Salinas, Matteo Cassina, Hannah Dunstan, Anneke Passier, Yusuf Cem Kaplan, Mine Kadioglu Duman, Eva Maňáková, Georgios Eleftheriou, Gil Klinger, Ursula Winterfeld, Laura E Rothuizen, Thierry Buclin, Chantal Csajka, Sonia Hernandez-Diaz
BACKGROUND: Metformin is used to treat type 2 diabetes, polycystic ovary syndrome associated infertility, and gestational diabetes. Human studies evaluating the safety of metformin in early pregnancy are scarce. METHOD: We evaluated the risk of major birth defects and pregnancy losses in a cohort of pregnant women exposed to metformin during first trimester for different indications relative to a matched unexposed reference group. RESULTS: The risk of major birth defects was 5...
December 7, 2017: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/29211393/the-impact-of-metformin-use-on-the-risk-of-prostate-cancer-after-prostate-biopsy-in-patients-with-high-grade-intraepithelial-neoplasia
#8
Lucio Dell'Atti, Andrea B Galosi
PURPOSE: We report our experience on metformin use in diabetic patients and its impact on prostate cancer (PCa) after a high-grade prostatic intraepithelial neoplasia (HGPIN) diagnosis. MATERIALS AND METHODS: We retrospectively analyzed 551 patients with a diagnosis of HGPIN without PCa in a first prostate biopsy. The cohort of the study consisted of 456 nondiabetic subjects, and 95 diabetic patients. Among the patients with diabetes 44 were treated with metformin, and 51 with other antidiabetic drugs...
December 7, 2017: International Braz J Urol: Official Journal of the Brazilian Society of Urology
https://www.readbyqxmd.com/read/29198069/does-metformin-exposure-before-icu-stay-have-any-impact-on-patients-outcome-a-retrospective-cohort-study-of-diabetic-patients
#9
Sebastien Jochmans, Jean-Emmanuel Alphonsine, Jonathan Chelly, Ly Van Phach Vong, Oumar Sy, Nathalie Rolin, Olivier Ellrodt, Mehran Monchi, Christophe Vinsonneau
BACKGROUND: Impact of metformin exposure before ICU stay remains controversial. Metformin is thought to induce lactic acidosis and haemodynamic instability but may reduce ICU mortality. We evaluated its influence on outcome in diabetic patients admitted in the ICU and then compared two different populations based on the presence of septic shock. METHODS: We conducted a retrospective cohort study in a 24-bed French ICU between October 2010 and December 2013, including all ICU-admitted diabetic patients...
December 2, 2017: Annals of Intensive Care
https://www.readbyqxmd.com/read/29181788/mortality-associated-with-metformin-versus-sulfonylurea-initiation-a-cohort-study-of-veterans-with-diabetes-and-chronic-kidney-disease
#10
Zachary A Marcum, Christopher W Forsberg, Kathryn P Moore, Ian H de Boer, Nicholas L Smith, Edward J Boyko, James S Floyd
BACKGROUND: For patients with type 2 diabetes and chronic kidney disease (CKD), high-quality evidence about the relative benefits and harms of oral glucose-lowering drugs is limited. OBJECTIVE: To evaluate whether mortality risk differs after the initiation of monotherapy with either metformin or a sulfonylurea in Veterans with type 2 diabetes and CKD. DESIGN: Observational, national cohort study in the Veterans Health Administration (VHA)...
November 27, 2017: Journal of General Internal Medicine
https://www.readbyqxmd.com/read/29174300/long-term-treatment-with-metformin-in-type-2-diabetes-and-methylmalonic-acid-post-hoc-analysis-of-a-randomized-controlled-4-3year-trial
#11
Mattijs Out, Adriaan Kooy, Philippe Lehert, Casper A Schalkwijk, Coen D A Stehouwer
AIMS: Metformin treatment is associated with a decrease of serum vitamin B12, but whether this reflects tissue B12 deficiency is controversial. We studied the effects of metformin on serum levels of methylmalonic acid (MMA), a biomarker for tissue B12 deficiency, and on onset or progression of neuropathy. METHODS: In the HOME trial, 390 insulin-treated patients with type 2 diabetes were treated with metformin or placebo for 52months. In a post hoc analysis, we analyzed the association between metformin, MMA and a validated Neuropathy Score (NPS)...
February 2018: Journal of Diabetes and its Complications
https://www.readbyqxmd.com/read/29168915/a-novel-microdevice-for-rapid-neutrophil-purification-and-phenotyping-in-type-2-diabetes-mellitus
#12
Hui Min Tay, Rinkoo Dalan, King Ho Holden Li, Bernhard O Boehm, Han Wei Hou
Neutrophil dysfunction is strongly linked to type 2 diabetes mellitus (T2DM) pathophysiology, but the prognostic potential of neutrophil biomarkers remains largely unexplored due to arduous leukocyte isolation methods. Herein, a novel integrated microdevice is reported for single-step neutrophil sorting and phenotyping (chemotaxis and formation of neutrophil extracellular traps (NETosis)) using small blood volumes (fingerprick). Untouched neutrophils are purified on-chip from whole blood directly using biomimetic cell margination and affinity-based capture, and are exposed to preloaded chemoattractant or NETosis stimulant to initiate chemotaxis or NETosis, respectively...
November 23, 2017: Small
https://www.readbyqxmd.com/read/29144162/association-between-metformin-adherence-and-all-cause-mortality-among-new-users-of-metformin-a-nested-case-control-study
#13
Patrice Simard, Nancy Presse, Louise Roy, Marc Dorais, Brian White-Guay, Agnès Räkel, Sylvie Perreault
BACKGROUND: Metformin presents better survival rates than other oral antidiabetics in the treatment of type 2 diabetes. However, these benefits may be dampened by inadequate treatment adherence. OBJECTIVE: We aimed to investigate the relationship between adherence level to metformin therapy and all-cause mortality over 10 years in incident metformin users. METHODS: A nested case-control study was conducted using a large cohort of beneficiaries of the Quebec public drug insurance plan, aged 45 to 85 years, who initiated metformin between 2000 and 2009...
November 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/29138876/lower-risk-of-dementia-with-pioglitazone-compared-with-other-second-line-treatments-in-metformin-based-dual-therapy-a-population-based-longitudinal-study
#14
Chieh-Hsiang Lu, Chen-Yi Yang, Chung-Yi Li, Cheng-Yang Hsieh, Huang-Tz Ou
AIMS/HYPOTHESIS: The effect of pioglitazone was compared with that of other second-line glucose-lowering drugs on the risk of dementia among individuals with type 2 diabetes receiving metformin-based dual therapy. METHODS: A total of 204,323 individuals with type 2 diabetes aged ≥18 years who were stable metformin users and dementia-free before the initiation of second-line glucose-lowering medication were identified in the period 2000-2011 from Taiwan's National Health Insurance Research Database and followed to the end of 2013...
November 14, 2017: Diabetologia
https://www.readbyqxmd.com/read/29108130/comparative-risk-of-serious-hypoglycemia-with-oral-antidiabetic-monotherapy-a-retrospective-cohort-study
#15
Charles E Leonard, Xu Han, Colleen M Brensinger, Warren B Bilker, Serena Cardillo, James H Flory, Sean Hennessy
PURPOSE: To examine and compare risks of serious hypoglycemia among antidiabetic monotherapy-treated adults receiving metformin, a sulfonylurea, a meglitinide, or a thiazolidinedione. METHODS: We performed a retrospective cohort study of apparently new users of monotherapy with metformin, glimepiride, glipizide, glyburide, pioglitazone, rosiglitazone, nateglinide, or repaglinide within a dataset of Medicaid beneficiaries from California, Florida, New York, Ohio, and Pennsylvania...
November 6, 2017: Pharmacoepidemiology and Drug Safety
https://www.readbyqxmd.com/read/29075499/metformin-therapy-and-postoperative-atrial-fibrillation-in-diabetic-patients-after-cardiac-surgery
#16
Suresh Basnet, Andrzej Kozikowski, Haiyan Sun, Melissa Troup, Luis E Urrutia, Renee Pekmezaris
BACKGROUND: Postoperative atrial fibrillation (AF) commonly occurs in cardiac surgery patients. Studies suggest inflammation and oxidative stress contribute to postoperative AF development in this patient population. Metformin exerts an anti-inflammatory effect that reduces oxidative stress and thus may play a role in preventing postoperative AF. METHODS: We conducted a matched, retrospective cohort study of diabetic patients' age ≥18 undergoing a coronary artery bypass graft (CABG) and/or cardiac valve surgery from January 1, 2009, to November 30, 2014...
2017: Journal of Intensive Care
https://www.readbyqxmd.com/read/29069850/metformin-use-and-survival-outcomes-in-endometrial-cancer-a-systematic-review-and-meta-analysis
#17
Weimin Xie, Tianjia Li, Jing Yang, Mengmeng Shang, Ying Xiao, Qian Li, Jiaxin Yang
Previous studies have evaluated the effects of metformin use on survival outcomes in endometrial cancer, but their results are inconsistent. We conducted a systematic review and meta-analysis to provide a quantitative assessment of the drug's effects based on available evidence. We searched PubMed, Embase, and the Cochrane Central Register of Controlled Trials to identify relevant studies that evaluated the association between metformin use on survival outcomes in endometrial cancer. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated to evaluate the association of metformin use with overall survival and with progression-free survival using a fixed-effects model...
September 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/29063073/the-association-between-metformin-use-and-colorectal-cancer-survival-among-patients-with-diabetes-mellitus-an-updated-meta-analysis
#18
Shan Tian, Hong-Bo Lei, Yu-Lan Liu, Yan Chen, Wei-Guo Dong
OBJECTIVE: Recent studies have reported conflicting results on the correlation between metformin use and outcomes in patients with colorectal cancer (CRC). A meta-analysis was performed to evaluate the efficacy of metformin therapy on the prognosis of CRC patients with type 2 diabetes mellitus (T2DM). METHODS: We conducted a systematic search of PubMed, EMBASE, the Cochrane Library, and the Web of Science for related articles up to August 2016. Two investigators independently identified and extracted information...
September 2017: Chronic Diseases and Translational Medicine
https://www.readbyqxmd.com/read/29054569/cause-specific-mortality-in-endometrioid-endometrial-cancer-patients-with-type-2-diabetes-using-metformin-or-other-types-of-antidiabetic-medication
#19
R Arima, A Hautakoski, M Marttila, M Arffman, R Sund, P Ilanne-Parikka, J Kangaskokko, M Hinkula, U Puistola, E Läärä
AIM: To obtain further evidence of the association between metformin or other types of antidiabetic medication (ADM) and mortality from endometrial cancer (EC) and other causes of death in patients with endometrioid EC and type 2 diabetes (T2D). MATERIALS AND METHODS: A retrospective cohort of women with existing T2D and diagnosed with endometrioid EC from 1998 to 2011, obtained from a nationwide diabetes database (FinDM), were included in the study. Cumulative mortality from EC and that from other causes was described by using the Aalen-Johansen estimator...
December 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/29051159/metformin-use-may-moderate-the-effect-of-dpp-4-inhibitors-on-cardiovascular-outcomes
#20
Matthew J Crowley, John W Williams, Andrzej S Kosinski, David A D'Alessio, John B Buse
OBJECTIVE: To explore prevalent metformin use as a potential moderator of the cardiovascular effects of dipeptidyl peptidase 4 inhibitors (DPP-4i). RESEARCH DESIGN AND METHODS: We performed a meta-analysis of the three major cardiovascular outcomes trials examining DPP-4i. We used meta-regression to examine how the cardiovascular effects of DPP-4i differ between prevalent metformin users and baseline nonusers. RESULTS: While prevalent metformin users experienced a trend toward improved cardiovascular outcomes with DPP-4i (summary hazard ratio [HR] 0...
December 2017: Diabetes Care
keyword
keyword
90703
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"